257 related articles for article (PubMed ID: 17374617)
1. Glycoengineering of alphaGal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope.
Sadoulet MO; Franceschi C; Aubert M; Silvy F; Bernard JP; Lombardo D; Mas E
Glycobiology; 2007 Jun; 17(6):620-30. PubMed ID: 17374617
[TBL] [Abstract][Full Text] [Related]
2. The formation of the oncofetal J28 glycotope involves core-2 beta6-N-acetylglucosaminyltransferase and alpha3/4-fucosyltransferase activities.
Panicot L; Mas E; Pasqualini E; Zerfaoui M; Lombardo D; Sadoulet MO; El Battari A
Glycobiology; 1999 Sep; 9(9):935-46. PubMed ID: 10460835
[TBL] [Abstract][Full Text] [Related]
3. Relationship between alphaGal epitope expression and decrease of tumorigenicity in pancreatic adenocarcinoma model.
Aubert M; Crotte C; Benkoel L; Panicot-Dubois L; Bernard JP; Lombardo D; Sadoulet MO; Mas E
Mol Carcinog; 2005 Apr; 42(4):202-12. PubMed ID: 15761838
[TBL] [Abstract][Full Text] [Related]
4. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
5. The oncofetal J28 epitope involves fucosylated O-linked oligosaccharide structures of the fetoacinar pancreatic protein.
Mas E; Crotte C; Lecestre D; Michalski JC; Escribano MJ; Lombardo D; Sadoulet MO
Glycobiology; 1997 Sep; 7(6):745-52. PubMed ID: 9376677
[TBL] [Abstract][Full Text] [Related]
6. Decrease of human pancreatic cancer cell tumorigenicity by alpha1,3galactosyltransferase gene transfer.
Aubert M; Crotte C; Bernard JP; Lombardo D; Sadoulet MO; Mas E
Int J Cancer; 2003 Dec; 107(6):910-8. PubMed ID: 14601050
[TBL] [Abstract][Full Text] [Related]
7. A novel tumor-associated pancreatic glycoprotein is internalized by human dendritic cells and induces their maturation.
Franceschi C; Collignon A; Isnardon D; Benkoel L; Vérine A; Silvy F; Bernard JP; Lombardo D; Beraud E; Olive D; Mas E
J Immunol; 2011 Apr; 186(7):4067-77. PubMed ID: 21346236
[TBL] [Abstract][Full Text] [Related]
8. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
9. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
10. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose.
LaTemple DC; Henion TR; Anaraki F; Galili U
Cancer Res; 1996 Jul; 56(13):3069-74. PubMed ID: 8674064
[TBL] [Abstract][Full Text] [Related]
12. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene.
Deriy L; Ogawa H; Gao GP; Galili U
Cancer Gene Ther; 2005 Jun; 12(6):528-39. PubMed ID: 15818383
[TBL] [Abstract][Full Text] [Related]
13. Integrin alpha3beta1 expressed by human colon cancer cells is a major carrier of oncodevelopmental carbohydrate epitopes.
Prokopishyn NL; Puzon-McLaughlin W; Takada Y; Laferté S
J Cell Biochem; 1999 Feb; 72(2):189-209. PubMed ID: 10022502
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review).
Huai G; Qi P; Yang H; Wang Y
Int J Mol Med; 2016 Jan; 37(1):11-20. PubMed ID: 26531137
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination.
Freire T; Lo-Man R; Piller F; Piller V; Leclerc C; Bay S
Glycobiology; 2006 May; 16(5):390-401. PubMed ID: 16449349
[TBL] [Abstract][Full Text] [Related]
16. [Pancreatic cancer-associated new carbohydrate antigen].
Yuan M
Zhonghua Zhong Liu Za Zhi; 1987 May; 9(3):183-6, 11. PubMed ID: 2452061
[TBL] [Abstract][Full Text] [Related]
17. The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.
Mandell RB; Flick R; Staplin WR; Kaniewski LD; Carzoli AK; Manuszak RP; Wang J; Rossi GR; Vahanian NN; Link CJ
Zoonoses Public Health; 2009 Aug; 56(6-7):391-406. PubMed ID: 19486321
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Lewis lung tumor development in alpha 1,3 galactosyltransferase knock-out mice.
Posekany KJ; Pittman HK; Swanson MS; Haisch CE; Verbanac KM
Anticancer Res; 2004; 24(2B):605-12. PubMed ID: 15161001
[TBL] [Abstract][Full Text] [Related]
19. Reduction of alpha-galactosyl xenoantigen by expression of endo-beta-galactosidase C in pig endothelial cells.
Ogawa H; Kobayashi T; Yokoyama I; Nagatani N; Mizuno M; Yoshida J; Kadomatsu K; Muramatsu H; Nakao A; Muramatsu T
Xenotransplantation; 2002 Jul; 9(4):290-6. PubMed ID: 12060465
[TBL] [Abstract][Full Text] [Related]
20. A novel method to display [gal alpha1, 3 gal] antigens on human leukemic cells for preparation of anti-leukemia vaccines.
Posekany KJ; Wiley JE; Gagnon GA
Anticancer Res; 2009 Jun; 29(6):2387-92. PubMed ID: 19528506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
